1. What Are UGTs?
UDP-glucuronosyltransferases (UGTs) are drug-metabolizing enzymes that catalyze glucuronidation, a major conjugative metabolic pathway for many endogenous compounds and therapeutic drugs.
In a typical glucuronidation reaction, a UGT transfers glucuronic acid from the co-substrate UDP-glucuronic acid (UDPGA) to a suitable functional group on the substrate. The resulting glucuronide is often more polar than the parent compound and may be eliminated through renal or biliary pathways.
UGT enzymes catalyze glucuronidation using UDPGA as the glucuronic acid donor. PBPK models translate this metabolic process into tissue-specific clearance terms.
2. Why Is UGT-Mediated Metabolism Important in PBPK?
Many PBPK workflows have historically focused heavily on CYP-mediated metabolism, but UGTs can make substantial contributions to the clearance of drugs and drug metabolites. A contemporary PBPK model may therefore need to represent UGT pathways explicitly when glucuronidation contributes materially to disposition.
UGT metabolism can occur in multiple tissues. Hepatic UGT activity is often important for systemic clearance, while intestinal UGTs can contribute to presystemic metabolism after oral administration.
| PBPK question | UGT-related information | Potential consequence |
|---|---|---|
| Is the drug metabolized by UGTs? | Reaction phenotyping and metabolite identification | Determines whether a UGT pathway should be represented |
| Which UGT isoforms contribute? | Recombinant enzyme and/or selective inhibition studies | Determines enzyme-specific contributions |
| How rapidly does glucuronidation occur? | Vmax and Km | Determines concentration-dependent intrinsic clearance |
| How much activity exists in vivo? | Scaling factors and tissue abundance/activity information | Connects in vitro activity to physiological clearance |
| Does intestinal metabolism matter? | Intestinal UGT expression/activity and oral route | Can influence bioavailability and first-pass extraction |
| Could an inhibitor alter exposure? | UGT inhibition parameters and perpetrator concentrations | Can support mechanistic DDI prediction |
The central PBPK challenge is therefore a translation problem: how do measurements made in an in vitro enzyme system become an estimate of metabolic clearance in a living human?
3. The UGT Glucuronidation Reaction
A simplified representation of direct glucuronidation is:
The substrate can contain different functional groups that are suitable for glucuronidation. Depending on the drug, UGT-mediated metabolism can therefore involve different reaction products and different enzyme isoforms.
UGT activity is commonly investigated using human liver microsomes, recombinant UGT systems, hepatocytes, or other experimental systems. Recombinant enzymes are particularly useful for identifying which isoforms can catalyze formation of a particular metabolite, whereas microsomal or hepatocyte systems can provide information closer to the integrated activity of a biological system.
4. Which UGT Isoforms Are Relevant?
The human UGT family contains multiple isoforms with overlapping but distinct substrate specificities. Consequently, a PBPK model may need to represent metabolism at the isoform level rather than treating all UGT activity as one undifferentiated pathway.
Commonly encountered drug-metabolizing UGT isoforms include UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, UGT2B10, and UGT2B15, although the relevant set depends on the drug and metabolic reaction.
| Information source | Primary purpose | PBPK interpretation |
|---|---|---|
| Recombinant UGTs | Identify isoforms capable of forming the metabolite | Supports reaction phenotyping |
| Human liver microsomes | Measure aggregate hepatic microsomal activity | Provides integrated metabolic activity for scaling |
| Human hepatocytes | Measure metabolism in intact cells | Can capture broader cellular context |
| Selective inhibitors | Probe contribution of individual pathways | Can provide supporting evidence for enzyme assignment |
| Clinical DDI studies | Observe changes in human exposure | Can provide in vivo evidence supporting or challenging the mechanistic model |
Current regulatory guidance emphasizes characterizing the responsible UGT isoforms when a drug is mainly eliminated by direct glucuronidation. However, the quantitative contribution of each isoform can remain uncertain, particularly when multiple UGTs contribute to the same pathway.
5. UGT Enzyme Kinetics
For many metabolic reactions, the relationship between substrate concentration and metabolic rate can be approximated using Michaelis-Menten kinetics:
Here, \(v\) is the metabolic rate, \(C\) is the relevant substrate concentration, \(V_{\max}\) is the maximum metabolic rate, and \(K_m\) is the substrate concentration associated with half of \(V_{\max}\) under the Michaelis-Menten model.
At concentrations much lower than \(K_m\), the equation approximately becomes:
The ratio \(V_{\max}/K_m\) therefore behaves like an apparent intrinsic clearance under low-substrate conditions:
6. From UGT Activity to Intrinsic Clearance
Intrinsic clearance describes the ability of an enzyme system to remove drug independently of the physical limitations imposed by blood flow and tissue extraction.
For a linear metabolic pathway, an intrinsic clearance estimate can be obtained from the slope of the appropriate concentration-rate relationship. Under a simple Michaelis-Menten approximation at low concentrations:
For UGT-mediated metabolism, the experimentally determined activity may initially be expressed per unit of microsomal protein, per unit of recombinant enzyme, or using another experimental basis. PBPK modeling requires that activity ultimately be translated to a physiologically meaningful tissue-level quantity.
| Scale | Example quantity | Role in PBPK |
|---|---|---|
| Enzyme system | pmol/min/mg protein | Experimental metabolic activity |
| Kinetic parameters | Vmax, Km | Characterize rate versus concentration |
| Intrinsic clearance | Volume/time/mass basis | Intermediate quantity for IVIVE |
| Tissue clearance | Organ-level metabolic capacity | Used within the PBPK organ model |
| Systemic clearance | L/h | Emergent property of the complete physiological model |
This distinction is important because intrinsic clearance is not the same as hepatic clearance. Hepatic blood flow, unbound fraction, tissue composition, and other physiological factors determine how intrinsic metabolic capacity translates into organ-level extraction.
7. Representing Hepatic UGT Clearance
For a simplified liver model, hepatic clearance can be related to hepatic blood flow \(Q_H\), unbound fraction \(f_u\), and intrinsic clearance \(CL_{\mathrm{int}}\). Under a commonly used well-stirred approximation:
This equation illustrates the distinction between enzyme capacity and organ-level clearance.
When \(f_uCL_{\mathrm{int}}\) is small relative to hepatic blood flow, the liver operates in a relatively low-extraction regime and hepatic clearance is approximately proportional to \(f_uCL_{\mathrm{int}}\). When intrinsic clearance becomes very large, hepatic clearance approaches the blood-flow limit.
| Situation | Approximate behavior | Interpretation |
|---|---|---|
| Low intrinsic clearance | \(CL_H\approx f_uCL_{\mathrm{int}}\) | Changes in enzyme activity can strongly influence hepatic clearance |
| High intrinsic clearance | \(CL_H\rightarrow Q_H\) | Hepatic blood flow limits extraction |
| Intermediate regime | Both terms matter | Changes in binding, flow, and intrinsic clearance can interact |
A full PBPK model goes beyond this compact equation by representing physiological organ volumes, blood flows, tissue partitioning, and potentially multiple metabolic and transport pathways.
8. Intestinal UGT Metabolism
UGT activity is not restricted to the liver. Intestinal UGTs can contribute to the presystemic metabolism of orally administered drugs.
After oral administration, a drug can encounter metabolic enzymes in the intestinal wall before entering the systemic circulation. This means that intestinal glucuronidation can affect bioavailability even when hepatic metabolism is the dominant systemic clearance pathway.
For oral dosing, intestinal and hepatic metabolism can both contribute to first-pass loss before systemic exposure is observed.
This is one of the advantages of PBPK over a single empirical bioavailability parameter: the model can potentially distinguish intestinal and hepatic contributions and examine how physiological or drug-specific changes affect each component.
9. In Vitro–In Vivo Extrapolation for UGTs
In vitro–in vivo extrapolation (IVIVE) is the process of translating experimentally measured metabolic activity into an estimate of human in vivo clearance.
For UGTs, this translation can be challenging because enzyme activity measured in vitro does not automatically equal enzyme activity in the intact human organ.
A simplified conceptual chain is:
Scaling can involve quantities such as microsomal protein abundance, liver mass, enzyme abundance, relative activity factors, or other experimentally justified parameters.
For UGTs, uncertainty in enzyme abundance, recombinant-system activity, microsomal activity, assay conditions, and scaling factors can all influence the resulting PBPK prediction.
10. Choosing an Experimental System
Different experimental systems answer different questions. No single assay is guaranteed to provide all of the information needed for a PBPK model.
| System | Strength | Important consideration |
|---|---|---|
| Recombinant UGT | Isoform-specific characterization | May not reproduce the activity or environment of native tissue |
| Human liver microsomes | Integrated microsomal metabolism | Requires appropriate scaling to the liver |
| Human hepatocytes | More intact cellular environment | Enzyme expression and viability can vary across preparations |
| Intestinal preparations | Can inform intestinal metabolism | Scaling intestinal activity to the in vivo gut can be challenging |
| Clinical PK/DDI data | Directly informs human exposure | Usually cannot identify every mechanistic pathway by itself |
A robust PBPK workflow often uses several evidence sources rather than relying on one assay. This is especially important when multiple UGT isoforms or competing metabolic pathways are involved.
11. UGT Metabolism Often Competes With Other Clearance Pathways
A drug may be metabolized simultaneously by several UGTs, CYP enzymes, esterases, or other metabolic pathways and may also undergo renal or biliary excretion.
A PBPK model can represent these pathways separately:
This simple additive representation is appropriate only when the individual intrinsic clearance terms are defined consistently and the underlying assumptions support such decomposition.
The important modeling principle is that a measured total clearance does not automatically tell us how much of that clearance belongs to UGTs. Mechanistic evidence is needed to allocate clearance among pathways.
| Pathway | Possible PBPK representation |
|---|---|
| UGT glucuronidation | UGT-specific metabolic clearance |
| CYP oxidation | Enzyme-specific oxidative clearance |
| Other enzymes | Mechanistically defined intrinsic clearance |
| Renal filtration | Filtration based on unbound drug and GFR |
| Renal secretion/reabsorption | Transporter and/or mechanistic renal processes |
| Biliary excretion | Hepatic transporter-mediated or empirical biliary processes |
12. When UGT Metabolism Becomes Saturable
At low concentrations, glucuronidation may behave approximately linearly. As substrate concentration increases, however, enzyme capacity can become saturated.
The Michaelis-Menten equation illustrates this behavior:
When \(C\ll K_m\), metabolic rate is approximately proportional to concentration. When \(C\gg K_m\), the rate approaches \(V_{\max}\).
At low substrate concentration, the rate is approximately linear. At high concentration, the enzyme approaches its maximum metabolic capacity.
In a PBPK model, saturation can become important when predicted tissue concentrations enter a range where the enzyme is no longer operating in the approximately linear portion of its kinetic curve.
13. UGT-Mediated Drug-Drug Interactions
UGT enzymes can also participate in drug-drug interactions (DDIs). A perpetrator drug may inhibit an isoform responsible for the victim drug's glucuronidation, potentially increasing exposure when that pathway contributes materially to clearance.
A simplified competitive inhibition expression is:
where \(I\) is inhibitor concentration and \(K_i\) is an inhibition constant under the assumed mechanism.
A mechanistic PBPK DDI model can go further by predicting perpetrator concentrations over time and allowing the inhibitor concentration at the site of metabolism to change dynamically.
| Question | Mechanistic model input | Potential output |
|---|---|---|
| Is the victim a UGT substrate? | Reaction phenotyping | Candidate UGT pathway |
| Which isoform matters? | Isoform-specific metabolism data | Enzyme-specific contribution |
| Does the perpetrator inhibit the UGT? | \(K_i\), \(IC_{50}\), or appropriate mechanistic parameters | Reduced metabolic capacity |
| Is inhibition clinically relevant? | Predicted perpetrator concentrations and victim clearance contribution | Predicted exposure change |
Current ICH M12 guidance includes UGTs within the scope of enzyme-mediated DDI assessment and emphasizes a case-by-case approach for UGT substrate and inhibitor evaluations.
14. UGTs, Transporters, and the Fate of the Glucuronide
UGT metabolism should not always be considered in isolation. Formation of a glucuronide creates a metabolite whose subsequent disposition can itself affect the observed PK of the parent drug.
Depending on the drug, the glucuronide may undergo renal elimination, biliary secretion, or other processes. Some glucuronides can also participate in enterohepatic recirculation after biliary excretion and intestinal deconjugation.
For many applications, the glucuronide can be treated simply as a terminal metabolite. For other drugs, however, explicit metabolite modeling may be necessary because the metabolite has pharmacologic activity, contributes to toxicity, or materially affects the parent concentration-time profile.
15. How Is UGT Metabolism Added to a PBPK Model?
A practical UGT PBPK workflow can be organized into several stages.
- Identify the metabolic pathway. Determine whether direct glucuronidation contributes to drug disposition.
- Identify responsible UGT isoforms. Use reaction phenotyping and supporting evidence to determine which enzymes can form the relevant glucuronide.
- Characterize enzyme kinetics. Estimate \(V_{\max}\), \(K_m\), and, where relevant, inhibition parameters.
- Determine the appropriate in vitro system. Consider recombinant UGTs, human liver microsomes, hepatocytes, or intestinal preparations.
- Scale metabolic activity. Translate the experimental activity into tissue-level intrinsic clearance using appropriate scaling assumptions.
- Represent tissue-specific metabolism. Include hepatic and, where justified, intestinal UGT activity.
- Combine pathways. Represent UGT clearance alongside other metabolic and excretory pathways.
- Evaluate the model against clinical PK. Compare predicted and observed concentration-time profiles and exposure metrics.
- Refine uncertain parameters cautiously. Distinguish mechanistically supported parameters from empirical adjustments.
UGT PBPK modeling is a translation workflow: biochemical measurements are converted into physiological clearance and then evaluated against clinical observations.
16. Worked Example: Translating UGT Kinetics Into a PBPK Clearance Estimate
Consider a hypothetical drug whose hepatic metabolism is substantially mediated by a UGT pathway. Suppose an in vitro experiment provides the following simplified kinetic parameters:
- \(V_{\max}=2.0\ \mathrm{nmol/min/mg\ microsomal\ protein}\)
- \(K_m=10\ \mathrm{\mu M}\)
- Unbound fraction in blood: \(f_u=0.25\)
- Hepatic blood flow: \(Q_H=90\ \mathrm{L/h}\)
For illustration, suppose the microsomal activity has already been converted through an assumed scaling process into a hepatic intrinsic clearance of:
Step 1: Calculate the unbound intrinsic clearance term
Step 2: Apply the well-stirred hepatic model
Step 3: Interpret the result
The calculated hepatic clearance is substantially below the hepatic blood flow of 90 L/h. In this simplified example, the drug is therefore not operating at a flow-limited extraction boundary.
The example also illustrates why an in vitro enzyme activity value cannot simply be substituted directly for systemic clearance. Between the original assay result and the predicted clinical clearance are scaling assumptions, protein binding, tissue physiology, and the hepatic extraction relationship.
17. How Should a UGT PBPK Model Be Evaluated?
A UGT PBPK model should be evaluated against observations that are relevant to the intended use of the model.
- Concentration-time profiles: Does the model reproduce the observed shape and magnitude of exposure?
- AUC: Is overall exposure predicted adequately?
- Cmax: Is the predicted peak concentration consistent with observations?
- Clearance: Does the model produce a plausible systemic clearance?
- Route dependence: Does the model reproduce differences between IV and oral administration when both are available?
- Metabolite behavior: When relevant, does predicted glucuronide formation and disposition agree with observations?
- DDI behavior: If the model is intended for DDI prediction, does it reproduce appropriate clinical interaction data?
Evaluation should also consider whether the model behaves plausibly when parameters are perturbed. Sensitivity analysis can reveal whether predictions are strongly controlled by UGT parameters or by other parts of the model.
18. Where Does Uncertainty Enter UGT PBPK Modeling?
UGT PBPK models can contain uncertainty at several levels.
| Source | Example uncertainty | Potential impact |
|---|---|---|
| Reaction phenotyping | Uncertain isoform contribution | Incorrect allocation of metabolic capacity |
| Enzyme kinetics | \(V_{\max}\) or \(K_m\) variability | Different predicted concentration dependence |
| Assay system | Differences between recombinant and native enzyme activity | Scaling uncertainty |
| Enzyme abundance | Interindividual and tissue variability | Variable in vivo metabolic capacity |
| Protein binding | Uncertain \(f_u\) | Changes the relationship between intrinsic and hepatic clearance |
| Intestinal activity | Uncertain contribution to first-pass metabolism | Uncertain oral bioavailability |
| Clinical calibration | Limited human PK data | Greater dependence on model assumptions |
One practical strategy is to use sensitivity analysis to identify which assumptions have the largest effect on the intended prediction. This helps distinguish parameters that require better experimental characterization from parameters that have relatively little influence on the result.
19. What UGT PBPK Models Do Not Tell Us Automatically
A mechanistic UGT model can be scientifically useful without being a perfect representation of every biological process. Several cautions are therefore important.
- Enzyme activity is not automatically equivalent to in vivo clearance. IVIVE requires scaling assumptions.
- Isoform identification does not establish quantitative contribution. Multiple UGTs may contribute simultaneously.
- In vitro kinetics may not transfer directly to humans. Experimental conditions can affect apparent kinetic parameters.
- UGT clearance may be nonlinear. A constant intrinsic clearance can be inappropriate when concentrations approach the saturation range.
- Intestinal and hepatic metabolism are distinct processes. Their contributions should not automatically be combined into one clearance term.
- Glucuronide disposition can matter. For some drugs, the metabolite requires explicit modeling.
- Clinical calibration can obscure mechanistic uncertainty. A fitted model may reproduce observed PK while compensating for errors elsewhere in the model.
20. A Practical UGT PBPK Workflow
- Start with the clinical question. Is the goal to predict first-in-human PK, dose proportionality, oral bioavailability, DDI risk, or another endpoint?
- Characterize the drug's metabolism. Identify glucuronide metabolites and determine whether direct glucuronidation is quantitatively important.
- Perform reaction phenotyping. Identify relevant UGT isoforms using appropriate experimental systems.
- Measure enzyme kinetics. Characterize \(V_{\max}\), \(K_m\), and relevant inhibition parameters where appropriate.
- Characterize protein binding. Determine the fraction available to the metabolic system under relevant conditions.
- Estimate intrinsic clearance. Translate experimental activity into a consistent clearance quantity.
- Apply IVIVE. Scale activity to the appropriate human tissue compartment.
- Represent hepatic and intestinal metabolism separately. Include each pathway when supported by evidence.
- Integrate competing pathways. Add CYP, other enzyme, transporter, and renal pathways as appropriate.
- Evaluate against clinical PK. Compare predictions with observed data across routes, doses, and relevant populations.
- Perform sensitivity and uncertainty analyses. Identify parameters that materially control the prediction.
- Use the model for prediction only within its justified domain. Clearly distinguish experimentally established information from model-based inference.
21. Key Takeaways
- UGTs are important drug-metabolizing enzymes that catalyze glucuronidation using UDP-glucuronic acid as the glucuronic acid donor.
- UGT-mediated metabolism can contribute to hepatic clearance, intestinal first-pass metabolism, or both.
- Reaction phenotyping helps identify which UGT isoforms can metabolize a drug, but isoform identification alone does not establish quantitative contribution in humans.
- UGT enzyme kinetics can often be described using Michaelis-Menten relationships, with \(V_{\max}/K_m\) approximating intrinsic clearance under low-substrate conditions.
- Intrinsic clearance is not the same as hepatic clearance. Physiological factors such as hepatic blood flow and protein binding determine how intrinsic capacity translates into organ-level extraction.
- IVIVE is a central step in UGT PBPK modeling because in vitro activity must be scaled to human tissue physiology.
- UGT metabolism can be represented alongside CYP metabolism, other metabolic pathways, renal elimination, and transport processes within a mechanistic PBPK framework.
- UGT metabolism can become nonlinear when substrate concentrations approach the enzyme's saturation range.
- UGT inhibition can contribute to drug-drug interactions, and mechanistic PBPK models can integrate inhibitor concentrations over time with enzyme inhibition parameters.
- Glucuronide metabolites may require explicit modeling when their disposition or pharmacologic activity materially affects the clinical PK or PD profile.
- Uncertainty in enzyme abundance, assay systems, kinetic parameters, scaling factors, protein binding, and pathway contribution can materially affect PBPK predictions.
- A useful UGT PBPK model is not simply one that fits observed concentrations; its mechanistic assumptions should also be scientifically defensible for the intended application.
Where to Go Next
A natural progression is to study hepatic clearance in PBPK, followed by intestinal metabolism, transporter-mediated disposition, CYP-mediated metabolism, enzyme induction and inhibition, and integrated enzyme-transporter DDI models.
For UGT-specific modeling, the next step is to examine how UGT reaction phenotyping and intrinsic clearance are translated into whole-body PBPK parameters, including the treatment of multiple UGT isoforms, saturable metabolism, intestinal first-pass effects, and clinical DDI prediction.
References
- Food and Drug Administration / International Council for Harmonisation. ICH M12 Drug Interaction Studies. Final guidance, 2024. FDA guidance page.
- Food and Drug Administration / International Council for Harmonisation. ICH M12 Drug Interaction Studies: In Vitro DDI Assessments. Includes recommendations concerning UGT substrates, UGT inhibitors, and UGT-mediated drug interactions. FDA guidance document.
- Parrott N, et al. PBPK Modelling for Drugs Cleared by Non-CYP Enzymes: State-of-the-Art and Future Perspectives. The review summarizes clinical PBPK applications for UGTs and other non-CYP enzymes and discusses challenges in IVIVE and model development. PubMed.
- Rowland A, Miners JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and disposition. Reviews the biology and drug-metabolizing role of UGT enzymes.
- Williams JA, et al. Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs). Reviews UGT enzyme kinetics, glucuronidation, IVIVE, and PBPK considerations. PubMed.
- Kedderis GL, et al. Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Discusses intestinal glucuronidation, first-pass metabolism, and effects on bioavailability. PubMed.
- Stresser DM, Zientek MA. UDP-Glucuronosyl transferase mediated drug-drug interactions: An Industry perspective on recommended in vitro studies. Drug Metabolism and Pharmacokinetics, 2026. PubMed.